Alector, Inc. (ALEC) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Alector, Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases, including Alzheimer's and Parkinson's disease. The company operates in a single segment and relies heavily on its collaboration with GlaxoSmithKline (GSK) and its proprietary Alector Brain Carrier (ABC) platform for blood-brain barrier delivery.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Collaboration Revenue | $1,046 | $3,674 |
| Total Operating Expenses | $25,965 | $48,369 |
| Net Loss | $(22,930) | $(40,471) |
| Net Loss Per Share (Basic/Diluted) | $(0.21) | $(0.41) |
| Cash, Cash Equivalents, and Marketable Securities | $206,515 | $153,195 |
| Total Debt (Short-term + Long-term) | $9,767 | $9,689 |
| Accumulated Deficit | $(994,986) | $(869,598) |
Note: Cash, cash equivalents, and marketable securities are derived from the Balance Sheet ($76,962 + $129,553) and Note 1.
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by $2.6 million (71%) primarily due to lower manufacturing-related activity supporting the discontinued Nivisnebart Phase 2 study.
- Expense Reduction: Total operating expenses decreased by $22.4 million (46%). Research and Development (R&D) expenses dropped $15.8 million, and General and Administrative (G&A) expenses dropped $6.6 million. These reductions are attributed to workforce reductions initiated in late 2025 and the wind-down of the AL002 program.
- Improved Loss Profile: Net loss improved by $17.5 million compared to the prior year quarter, driven by the significant decrease in operating expenses.
- Restructuring: The company recorded a $0.3 million reduction to previously recognized restructuring costs in Q1 2026 due to lower-than-expected termination benefits.
Guidance, Outlook, and Risks
- Clinical Discontinuations: In April 2026, GSK discontinued the global Phase 2 PROGRESS-AD trial of nivisnebart following an interim futility analysis. The company also previously discontinued the Phase 3 INFRONT-3 trial of latozinemab (October 2025) and the AL002 program (November 2024).
- Pipeline Focus: The company is pivoting to its next-generation pipeline enabled by the ABC platform, including AL037/AL137 (anti-amyloid beta for Alzheimer's, targeting IND submission in Q1 2027), AL050 (GCase enzyme replacement for Parkinson's), and AL164 (tau siRNA for Alzheimer's).
- Liquidity and Runway: As of March 31, 2026, the company held $206.5 million in cash, cash equivalents, and marketable securities. Management anticipates this provides a runway at least through 2027.
- Debt Obligations: The company has a loan agreement with Hercules Capital allowing access to up to $50 million in term loans. $10 million was drawn as of the reporting date. The agreement includes restrictive covenants.
- Risks: Key risks include the failure of future clinical trials, the need for substantial additional financing, reliance on third-party collaborators (GSK), and the impact of macroeconomic conditions on capital markets.
Investor Verification Checklist
- Verify the specific timeline and cost implications of the wind-down of the nivisnebart and latozinemab programs.
- Confirm the status of the $140.5 million cost-sharing obligation with GSK for the nivisnebart Phase 2 trial.
- Monitor the progress of the ABC-enabled pipeline (AL037/AL137, AL050, AL164) toward IND-enabling studies.
- Review the terms of the Hercules Capital loan agreement for potential covenant triggers given the company's cash burn rate.
- Assess the impact of the 47% workforce reduction initiated in October 2025 on the company's ability to execute its new strategic priorities.